CureVac Takes Another Shot At mRNA Vaccines, Expands Cancer Work

Wants To Compete With Neighbors BioNTech

 
• By Andrew McConaghie
  
TUEBINGEN, GERMANY - NOVEMBER 21: (BILD ZEITUNG OUT) the Logo of Curevac is seen on a sign in front of the CUREVAC building on November 21, 2020 in Tuebingen, Germany.
CureVac is developing a multivalent flu vaccine and a bivalent COVID-19 candidate with GSK. • Source: Harry Langer/DeFodi Images via Getty Images (DeFodi Images/Getty Images)

More from Clinical Trials

More from R&D